1,069 results on '"Pope, Janet E."'
Search Results
2. Systemic Sclerosis (Scleroderma) and Raynaud’s Phenomenon
3. “From Where I Stand”: using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ)
4. State-of-the-art evidence in the treatment of systemic sclerosis
5. An Unusual Presentation of ANCA-Negative Granulomatosis With Polyangiitis (GPA) in the Gynecological Tract and Literature Review
6. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
7. Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?
8. Non-pharmacological interventions in the treatment of rheumatoid arthritis: A systematic review and meta-analysis
9. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial
10. Prevalence of osteoporosis in osteoarthritis: a systematic review and meta-analysis
11. Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies
12. Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial
13. Pregnancy Considerations for Patients With Interstitial Lung Disease
14. Health Care Utilization in Systemic Sclerosis Patients With Digital Ulcers
15. Arthritis in Systemic Sclerosis
16. Joint involvement in sarcoidosis: systematic review and meta-analysis of prevalence, clinical pattern and outcome.
17. Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study
18. Current and future status of JAK inhibitors
19. Osteoporosis and osteonecrosis in systemic lupus erythematosus
20. Pertinence des tests de laboratoire dans le diagnostic des rhumatismes inflammatoires chez des patients nouvellement orientés vers un rhumatologue
21. Increased Mortality for Individuals With Giant Cell Arteritis: A Population‐Based Study
22. Challenges of Perceived Self‐Management in Lupus
23. To choose or not? The value of discrete-choice experiments in rheumatology
24. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
25. Appropriateness of laboratory tests in the diagnosis of inflammatory rheumatic diseases among patients newly referred to rheumatologists
26. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
27. Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
28. Fréquence de l’uvéite chez les patients présentant une arthrite chronique juvénile
29. The future of treatment in systemic sclerosis: can we design better trials?
30. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
31. Performance of DETECT PAH algorithm according to the hemodynamic definition of pulmonary arterial hypertension (PAH) in the 2022 ESC/ERS guidelines
32. The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases
33. What Does the COVID-19 Pandemic Mean for Rheumatology Patients?
34. Raynaud’s phenomenon—an update on diagnosis, classification and management
35. Arthritis in Systemic Sclerosis
36. IgG4-Related Disease, A Single-Center Experience
37. Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #1
38. Possible benefit of tadalafil cream for the treatment of Raynaud’s phenomenon and digital ulcers in systemic sclerosis
39. Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial
40. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
41. Scleroderma epidemiology update
42. Preventative Care in Scleroderma
43. PROMs for Systemic Sclerosis (Scleroderma)
44. Novel treatment strategies in rheumatoid arthritis
45. IgG4-Related Disease, A Single-Center Experience
46. Drug Treatment of Raynaud’s Phenomenon
47. Systemic Lupus Erythematosus May Be a Risk Factor for Antimalarial‐Induced Retinopathy Compared With Other Rheumatologic Diseases
48. Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
49. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
50. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.